MarketCap
Facebook
X
Telegram
Silicon Laboratories Financial Ratios 2026-2007 | SLAB
Brief overview of Silicon Laboratories 's multiples and efficiency
Current figures are compared with the company's own five-year history for 2017–2022.
Key multiples at the end of the period are P/E 68.03x (median 88.69x), EV/EBITDA 45.6x (median 28.37x), P/S 8.61x (median 7.35x). On average, this basket is 39.5% above its own five-year medians. The market is pricing in elevated future expectations.
The 1/P/E calculation produces a 1.5% earnings yield. It does not capture future growth or capital structure.
Returns on assets and capital are represented by ROE -5.9%, ROA -5.1%, ROCE -6.4%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
PEG of 0.64x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.
The cash conversion cycle increased 89.2 days to 160.2 days, weakening working-capital efficiency.
Overall assessment
Silicon Laboratories 's valuation is above historical references while efficiency remains restrained, increasing sensitivity to weak reports.
Annual Financial Ratios Silicon Laboratories
| 2026 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-104.1 | -22.5 | -127.3 | 68.0 | 537.0 | - | 260.5 | 47.4 | 88.7 | 64.4 | 49.7 | - | 37.2 | 29.0 | 27.3 | 27.6 | 51.6 | - |
P/S |
8.6 | 7.3 | 5.6 | 6.1 | 13.2 | - | 6.0 | 4.6 | 5.4 | 3.0 | 3.0 | - | 3.2 | 3.3 | 4.0 | 4.6 | - | - |
EPS |
-2.0 | -5.9 | -1.1 | 2.6 | 0.3 | - | 0.4 | 1.9 | 1.1 | 1.5 | 0.9 | - | 1.2 | 1.5 | 0.8 | 1.6 | 0.7 | - |
EV (Enterprise Value) |
6.57 B | 4.15 B | 4.4 B | 6.48 B | 7.32 B | - | 5.35 B | 4.32 B | 4.49 B | 2.01 B | 2.03 B | - | 2.01 B | 1.96 B | 2 B | 1.93 B | 1.53 B | -264 M |
EBITDA per Share |
-1.4 | -4.35 | 0.05 | 4.04 | -2.07 | - | 2.61 | 3.36 | 2.99 | 1.75 | 1.91 | - | 2.19 | 2.69 | 2.36 | 1.74 | 1.13 | - |
EV/EBITDA |
-143.3 | -29.7 | 2833.2 | 45.7 | -80.3 | - | 45.6 | 28.4 | 33.5 | 25.1 | 22.3 | - | 20.2 | 16.6 | 17.5 | 24.7 | 28.1 | - |
PEG |
- | - | - | - | - | - | -3.38 | 0.64 | -3.62 | -3.08 | -2.06 | - | -1.64 | 0.35 | 51.0 | - | - | - |
P/B |
6.2 | 4.0 | 3.6 | 4.4 | 5.6 | - | 4.5 | 3.7 | 4.4 | 2.5 | 2.5 | - | 2.5 | 2.8 | 3.2 | 3.2 | - | - |
P/CF |
70.6 | -308.7 | -144.8 | - | - | - | 33.4 | 26.6 | 23.6 | 20.2 | 15.7 | - | 17.8 | -136.5 | 20.8 | 16.7 | 14.2 | - |
ROE % |
-5.93 | -17.69 | -2.86 | 6.51 | 1.04 | - | 1.73 | 7.83 | 4.94 | 3.89 | 5.01 | - | 6.74 | 9.77 | 11.70 | 11.61 | 6.55 | - |
ROA % |
-5.11 | -15.62 | -2.39 | 4.21 | 0.63 | - | 1.15 | 5.15 | 3.07 | 2.93 | 3.64 | - | 5.02 | 7.28 | 10.06 | 9.84 | - | - |
ROCE % |
-6.45 | -15.32 | -2.00 | 8.49 | -8.93 | - | 3.69 | 5.76 | 6.19 | 3.71 | 5.85 | - | 7.29 | 11.19 | 13.38 | 10.17 | 8.69 | - |
Current Ratio |
7.3 | 8.6 | 6.2 | 2.8 | 2.5 | - | 6.9 | 5.7 | 5.8 | 3.0 | 3.2 | - | 4.2 | 4.4 | 6.2 | 6.6 | - | - |
DSO |
15.0 | 26.2 | 23.5 | 29.7 | 34.0 | - | 33.0 | 30.8 | 33.9 | 41.7 | 41.4 | - | 45.4 | 50.5 | 33.3 | 23.2 | - | - |
DIO |
53.2 | 201.1 | 167.2 | 79.9 | 56.3 | - | 81.5 | 78.9 | 84.8 | 74.5 | 79.3 | - | 72.8 | 80.4 | 85.3 | - | - | - |
DPO |
28.2 | 67.0 | 83.6 | 69.3 | 46.4 | - | 43.4 | 43.3 | 45.1 | 58.2 | 58.6 | - | 35.5 | 48.0 | 52.7 | - | - | - |
Operating Cycle |
68.2 | 227.3 | 190.7 | 109.6 | 90.3 | - | 114.4 | 109.7 | 118.7 | 116.2 | 120.7 | - | 118.1 | 130.9 | 118.6 | 23.2 | - | - |
Cash Conversion Cycle |
40.0 | 160.2 | 107.1 | 40.3 | 43.9 | - | 71.1 | 66.3 | 73.6 | 57.9 | 62.0 | - | 82.6 | 82.9 | 65.9 | 23.2 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Silicon Laboratories
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2010-Q3 | 2010-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.67 | -0.48 | - | -0.3 | -0.67 | -0.94 | - | -0.88 | -2.56 | -1.77 | - | 0.33 | 0.35 | 0.44 | - | 0.62 | 0.62 | 0.6 | - | 48.11 | 0.44 | 0.31 | - | 0.07 | -0.04 | 0.05 | - | 0.47 | -0.37 | 0.12 | - | 0.64 | 0.33 | 0.61 | - | 0.47 | 0.39 | 0.37 | - | 0.48 | 0.37 | 0.14 | - | 0.24 | 0.18 | 0.15 | - | 0.13 | 0.33 | 0.19 | - | 0.15 | 0.3 | 0.47 | - | 0.24 | 0.48 | 0.34 | - | 0.26 | 0.3 | -0.04 | -0.04999999999999993 | 0.5 | 0.22 |
EBITDA per Share |
-0.7 | -0.33 | - | - | - | -0.8 | - | - | - | -1.65 | - | - | - | 0.81 | - | 1.37 | 0.88 | 1.02 | - | 0.08 | -0.26 | -0.24 | - | -0.27 | -0.55 | 0.19 | - | 0.84 | 0.53 | 0.21 | - | 0.85 | 0.59 | 0.64 | - | 0.85 | 0.66 | 0.39 | - | 0.76 | 0.58 | 0.24 | - | 0.48 | 0.35 | 0.24 | - | 0.44 | 0.63 | 0.31 | - | 0.48 | 0.6 | 0.57 | - | 0.9 | 0.54 | 0.48 | - | 0.56 | 0.51 | 0.19 | 1.51 | 0.66 | 0.29 |
ROE % |
-6.45 | -7.28 | -5.84 | -8.47 | -15.06 | -17.85 | -15.00 | -14.18 | -10.67 | -2.17 | 2.68 | 4.03 | 4.59 | 4.86 | 3.87 | 83.96 | 84.24 | 83.98 | 82.83 | 83.14 | 3.09 | 1.67 | 0.55 | 1.40 | 0.14 | 0.59 | 0.39 | 6.80 | 9.76 | 13.18 | 12.70 | 18.15 | 15.09 | 12.90 | 10.43 | 15.43 | 12.56 | 9.91 | 8.29 | 9.64 | 5.59 | 3.85 | 3.14 | 3.89 | 4.38 | 4.48 | 3.65 | 4.53 | 5.49 | 6.37 | 5.30 | 6.85 | 9.12 | 9.61 | 6.90 | 8.78 | 9.47 | 5.99 | 3.78 | 3.80 | 5.48 | 4.79 | 0.01 | 3.56 | 1.54 |
ROA % |
-5.55 | -6.31 | -5.06 | -7.34 | -13.12 | -15.54 | -13.06 | -12.36 | -9.36 | -2.14 | 2.07 | 2.97 | 3.07 | 60.61 | 59.97 | 61.02 | 60.12 | 60.84 | 60.04 | 60.22 | 1.98 | 1.04 | 0.32 | 0.89 | 0.07 | 0.37 | 0.26 | 4.47 | 6.41 | 8.67 | 8.34 | 11.73 | 9.60 | 8.10 | 6.47 | 10.30 | 8.89 | 7.34 | 6.34 | 7.36 | 4.26 | 2.91 | 2.38 | 2.93 | 3.30 | 3.37 | 2.75 | 3.41 | 4.13 | 4.76 | 3.95 | 5.10 | 6.80 | 7.17 | 5.14 | 6.74 | 7.48 | 4.85 | 3.21 | 3.22 | 4.65 | 4.07 | 0.01 | 3.02 | 1.31 |
ROCE % |
-6.98 | -7.87 | -6.31 | -9.06 | -12.30 | -15.22 | -12.21 | -11.24 | -7.13 | -1.36 | 3.71 | 5.66 | 6.65 | 6.95 | 5.58 | 5.22 | 2.34 | -0.83 | -2.51 | -4.52 | -6.92 | -5.62 | -4.40 | -2.27 | 1.06 | 4.26 | 3.90 | 6.25 | 5.80 | 6.72 | 6.26 | 8.88 | 8.73 | 8.37 | 6.15 | 8.78 | 8.29 | 6.92 | 5.59 | 7.10 | 5.62 | 4.43 | 3.60 | 4.88 | 6.05 | 6.22 | 5.27 | 6.69 | 7.99 | 8.11 | 6.79 | 10.98 | 12.04 | 11.97 | 9.18 | 11.43 | 9.82 | 8.13 | 5.62 | 6.06 | 7.87 | 7.24 | 0.44 | 4.06 | 1.95 |
Current Ratio |
7.3 | 7.5 | 7.3 | 6.9 | 7.6 | 7.6 | 8.6 | 7.4 | 8.0 | 7.5 | 6.2 | 6.9 | 5.8 | 2.9 | 2.8 | 3.0 | - | 3.4 | 2.5 | 3.7 | 2.8 | 2.8 | - | 2.5 | 2.5 | 2.3 | 3.0 | 3.0 | 3.0 | 3.0 | 2.9 | 2.9 | 2.9 | 2.9 | 2.6 | 2.6 | 2.6 | 2.6 | 4.2 | 4.2 | 4.2 | 4.2 | 3.7 | 4.1 | 4.2 | 4.0 | - | 3.8 | 4.2 | 4.1 | 3.9 | 3.9 | 3.9 | 3.9 | 3.9 | 3.9 | 3.9 | 3.9 | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 |
DSO |
33.5 | 30.3 | - | 27.4 | 25.7 | 27.4 | - | 24.7 | 23.2 | 26.6 | - | 44.9 | 34.6 | 29.4 | - | 13.0 | 13.7 | 34.0 | - | 42.5 | 54.7 | 30.0 | - | 51.9 | 57.9 | 31.9 | - | 30.9 | 33.4 | 36.1 | - | 29.0 | 30.8 | 32.1 | - | 32.8 | 34.3 | 37.1 | - | 38.1 | 38.8 | 40.8 | - | 38.7 | 38.2 | 18.6 | - | 40.5 | 39.4 | 42.8 | - | 44.8 | 46.5 | 47.1 | - | 47.6 | 52.5 | 48.4 | - | 42.4 | 40.0 | 42.5 | - | - | - |
DIO |
107.0 | 104.8 | - | 85.5 | 88.5 | 107.9 | - | 183.2 | 241.6 | 349.0 | - | 168.6 | 125.8 | 114.7 | - | 38.7 | 25.5 | 60.4 | - | 67.5 | 82.0 | 54.7 | - | 108.5 | 132.0 | 75.2 | - | 74.7 | 83.7 | 93.5 | - | 72.3 | 79.7 | 83.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
57.7 | 56.5 | - | 59.7 | 60.3 | 55.0 | - | 50.3 | 55.6 | 90.8 | - | 55.6 | 57.1 | 79.2 | - | 35.8 | 29.6 | 69.8 | - | 78.0 | 87.2 | 47.6 | - | 68.9 | 78.7 | 43.1 | - | 39.8 | 44.6 | 50.6 | - | 39.7 | 43.8 | 45.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 135.1 | - | 113.0 | 114.1 | 135.2 | - | 207.9 | 264.8 | 375.6 | - | 213.5 | 160.5 | 144.1 | - | 51.7 | 39.3 | 94.5 | - | 110.0 | 136.7 | 84.7 | - | 160.4 | 189.9 | 107.1 | - | 105.6 | 117.1 | 129.6 | - | 101.3 | 110.5 | 115.4 | - | 32.8 | 34.3 | 37.1 | - | 38.1 | 38.8 | 40.8 | - | 38.7 | 38.2 | 18.6 | - | 40.5 | 39.4 | 42.8 | - | 44.8 | 46.5 | 47.1 | - | 47.6 | 52.5 | 48.4 | - | 42.4 | 40.0 | - | - | - | - |
Cash Conversion Cycle |
- | 78.6 | - | 53.2 | 53.8 | 80.3 | - | 157.6 | 209.2 | 284.8 | - | 157.9 | 103.3 | 65.0 | - | 15.9 | 9.7 | 24.7 | - | 31.9 | 49.5 | 37.0 | - | 91.5 | 111.2 | 63.9 | - | 65.8 | 72.5 | 79.0 | - | 61.6 | 66.7 | 70.4 | - | 32.8 | 34.3 | 37.1 | - | 38.1 | 38.8 | 40.8 | - | 38.7 | 38.2 | 18.6 | - | 40.5 | 39.4 | 42.8 | - | 44.8 | 46.5 | 47.1 | - | 47.6 | 52.5 | 48.4 | - | 42.4 | 40.0 | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Silicon Laboratories , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
China
Taiwan
Cayman-islands
Britain
Israel
Schweiz
France
